04.14.15
Salt Lake City, Utah-based Perseon Corporation has received 510(k) clearance from the U.S. Food and Drug Administration for a new indication for the Microthermx microwave ablation system. The system is now OK’d for ablation procedures requiring partial or complete ablation of non-resectable liver tumors.
“This expanded indication for the Microthermx gives hospitals and patients another option for the treatment of complicated non-resectable liver tumors using microwave ablation,” said Perseon Director Damian E. Dupuy, M.D. “The expanded clinical applications combined with the ease of use and attractive economics make the Microthermx the leading microwave ablation product on the market today.”
“A pillar of our strategic plan outlined earlier this year is to make Perseon more clinically relevant through clinical data and expanded indications to fight humanity’s worst disease—cancer, and we continue to execute on our strategic plan,” said Clint Carnell, CEO of Perseon. “The recent appointment of Brian Meltzer, M.D. as Chief Medical Officer, our announcement last week about our new indication for laparoscopic ablation, and the expanded indication for non-resectable liver tumors all demonstrate outstanding clinical momentum and business execution in expanding the market for our ablation products.”
The system was cleared for laparoscopic ablation procedures using image guidance in earlier this month.
Perseon makes medical systems that use heat therapy to treat cancer.
“This expanded indication for the Microthermx gives hospitals and patients another option for the treatment of complicated non-resectable liver tumors using microwave ablation,” said Perseon Director Damian E. Dupuy, M.D. “The expanded clinical applications combined with the ease of use and attractive economics make the Microthermx the leading microwave ablation product on the market today.”
“A pillar of our strategic plan outlined earlier this year is to make Perseon more clinically relevant through clinical data and expanded indications to fight humanity’s worst disease—cancer, and we continue to execute on our strategic plan,” said Clint Carnell, CEO of Perseon. “The recent appointment of Brian Meltzer, M.D. as Chief Medical Officer, our announcement last week about our new indication for laparoscopic ablation, and the expanded indication for non-resectable liver tumors all demonstrate outstanding clinical momentum and business execution in expanding the market for our ablation products.”
The system was cleared for laparoscopic ablation procedures using image guidance in earlier this month.
Perseon makes medical systems that use heat therapy to treat cancer.